Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery - Top-Institutions - MDSpire

Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

  • By

  • June 12, 2026

  • 3 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Lank Center for Genitourinary Oncology
    Lank Center for Genitourinary Oncology

    Boston, MA

    Key Differentiators

    • Genitourinary Oncology

  • #3

    Vanderbilt University Medical Center
    Vanderbilt University Medical Center

    Nashville, TN

    Key Differentiators

    • Oncology

Original Source(s)

Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

  • by

  • June 12, 2026

Related Content

Motor mapping to enable resections of peri-rolandic diffuse gliomas

A hybrid ViT-L/32–MaxViT-L architecture with adaptive gated fusion for multiclass gastrointestinal disease detection and multi-method post-hoc explainability

Deep learning-based malignancy probability estimation of pulmonary nodules in PET/CT imaging